Navigation Links
Zilver 518 Biliary Stent

ProductsZilver 518 Biliary Stent
Company Cook Incorporated
Item Zilver 518 Biliary Stent
Features 
  • Self-expandable stent made of nitinol.
  • Flexible, fine mesh slotted tube which provides strength and flexibility in the biliary duct upon deployment.
  • Supplied with multiple gold markers in each end for precise placement in the lumen.
  • Preloaded in a 5.0 French OD Flexor introducer - designed to provide maximum flexibility without kinking or compressing.
  • Recommended 5.0 French sheath/7.0 French guiding catheter size.
  • Accepts .018 inch diameter wire guide.
Description The Zilver 518 Biliary Stent, a flexible, self-expanding nitinol design intended to treat patients with malignant neoplasms in the biliary system, is now available from Cook Incorporated following clearance by the U.S. Food and Drug Administration. Incorporating the features that have made Cook's line of Zilver stents successful around the world, the Zilver 518 provides physicians with a 5 French-compatible, lower profile system delivered over a .018 inch wire guide to facilitate its use in smaller lumens.
Info Cook Incorporated
Customer Service: (800) 457-4500
Web site: http://www.cookgroup.com/

Related medicine products :

1. Express Biliary SD Stent System 150 cm
2. Express Biliary SD Stent System 90 cm
3. Sentinol™ Self-Expanding Nitinol Biliary Stent System
4. Spencer Modified Biliary Wire Guides
5. ABSOLUTE™ 0.035 Biliary Self-Expanding Stent System
6. OMNILINK® 0.035 Biliary Stent System
7. DYNALINK® 0.018 Biliary Self-Expanding Stent System
8. RX HERCULINK® PLUS Biliary Stent System
9. WaveMax Biliary Stent
10. Cypher Stent
11. Cypher Sirolimus-eluting Coronary Stent
Near and far chart set provides letter and number matrix for testing and accommodative vision training. Set includes 1-8 1/2 X 11 chart on white card with black print and 2-3X5 laminated white card w
Rosenbaum card fits in the pocket (3.5 by 6.5") and shows point, Jaeger and distance equivalents from 20/800 to 20/20. Uses numbers, directional Es and XO patterns. For use at 14" (35 mm). Includes f
...ally designed to be a corrected Rosenbaum card. Th...as noted by Horton and Jones in 1997 and others) h... because of the lack of standards associated with ...xaminer can measure a patients single letter near ...
...ding card was designed by James Lebensohn, MD and ...uding words, numbers and OX symbols. Optotypes inc... 20/50, 20/40, 20/30, 20/25, and 20/20. Notation e...metric, Jaeger, point size and visual efficiency p...
Medicine Products:
(Date:11/21/2008)...fresh from basic training and now serving overseas...fe he saved by donating his rare blood type. , ... Korea (PRWEB) November 21, 2008 -- A local Korean...on saved her life, met for the first time when she...Airman Tamarias Pope, 8th Security Forces Squadron...
(Date:11/21/2008)...eld on January 8, 2009 , , TORONTO, Nov. 21...Inc. ("MedEmerg") (OTCBB: MDER), one of Canada,s l...ay that it has obtained an interim order from the ...reviously announced plan of arrangement (the "Arra...("AIM") will acquire all of MedEmerg,s outstanding...
(Date:11/21/2008)...rstCall/ -- Heska Corporation,(Nasdaq: HSKA ) t...iety of,Security Analysts, 12th Annual Biotech an... at 1177 Avenue of the Americas, 2nd Floor in New ...at 9:35 a.m. Eastern Time (7:35 a.m.,Mountain Tim...two weeks,following the presentation through a li...
(Date:11/21/2008)...gainst Lennox-Gastaut syndrome , , FRIDA...anzel (rufinamide) has been approved as a suppleme...ed Lennox-Gastaut syndrome, the U.S. Food and Drug...l was based on results of a four-month clinical tr...to patients who took a placebo, those who took the...
Breaking Medicine News(10 mins):Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 2Health News:Life-Saving Airman, Leukemia Patient Meet for First Time 3Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...stitute had discovered a new molecular explanation...ed behavior in the disease called porphyria, the d...king George III. The Dana-Farber scientists say i...e August 26 issue of the journal Cell that the nut...
...ought of as a as paranormal phenomena, may in fact...ience their own bodies. Despite the high incidence...nown about the phenomenon. Around 10% of the popul...OBE) at some time, typically involving a sensation...
...colloborate with Nobex Corporation of United State...cular diseases. The spokesperson of Biocon informe...ollaboration // on Tuesday for development of pept...ar diseases. The Biocon press release said, “The c...
... September issue of the Harvard Health Letter, fro... that advocate quick and short working out session...ealth conditions that can lead to diseases. To pre... longer and strenuous workout sessions are require...
Other Medicine News:Health News:Study Unveils New Insight To The Madness Of King George III 2
(Date:11/20/2008)...RNewswire-FirstCall/ -- Duska Therapeutics,Inc.,...it has submitted its,pivotal Phase 3 ATPace clini...tocol Assessment (SPA) procedure with the U.S. Foo... to securing an agreement with the FDA, Duska inte...nd, placebo-controlled and randomized Phase 3,cli...
(Date:11/20/2008)...e/ -- Clinical data from a prospective,registry p...ium shows DVT,treatment with the Trellis(R) Perip... (Santa Clara, CA) successfully breaks up the bloo... This technique, called isolated pharmacomecha...kly and safely than current catheter-directed thro...
(Date:11/20/2008)... 20 The Scandinavian-based drug,d...esults of studies on its,lead antimicrobial candi...,the studies showed that the novel lytic peptido...significantly better towards killing Staphylococcu... gold standard drugs. In,addition to this it has ...
(Date:11/19/2008)...19 Amgen,(Nasdaq: AMG... subsidiary of,Takeda Pharmaceutical Company Limi...in the Phase 3 MONET1 trial evaluating motesanib (...platin for the first-line treatment of,advanced n...rily suspended,following a planned safety data re...
Breaking Medicine Technology:Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7International Society of Hair Restoration Surgery and Istituto Dermopatico dellImmacolata Host Made In Italy 3A Hair Restoration Live Video Surgery Wo 19268 1International Society of Hair Restoration Surgery and Istituto Dermopatico dellImmacolata Host Made In Italy 3A Hair Restoration Live Video Surgery Wo 19268 2Personalized Plates for Picky Palates 3A Moms can Satisfy all With One Recipe Four Ways 19266 1Personalized Plates for Picky Palates 3A Moms can Satisfy all With One Recipe Four Ways 19266 2NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 1NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 2NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 3NightHawk Radiology Holdings Inc Announces Dutch Tender Offer for Its Common Stock 19264 4StemCor Systems Inc Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 5376 1StemCor Systems Inc Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 5376 2StemCor Systems Inc Awarded NIH SBIR Grant for Bone Marrow Aspiration Platform 5376 3
...nal protection against,infection with virus types ...idate vaccine, PHILADELPHIA, June 27, 2007 /PRNews...s of a Phase III study show that,CERVARIX(R), the ...,provides up to 100 percent protection against adv...on types of human papillomavirus,types 16 and 18....
...h VELCADE, cyclophosphamide,and prednisone alive ...ire-FirstCall/ -- Millennium,Pharmaceuticals, Inc....m clinical trials of VELCADE based therapies that ...(1) (CR) rates in previously,treated multiple myel...t the prestigious 11th International Myeloma Works...
Other Medicine Technology:Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 2Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 3Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 4Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 5Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 6Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix,Provides Excellent Protection Against Lesions Caused by Most Common,Cancer-Causing Virus Types 7Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 2Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 3Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 4Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 5Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma 6